Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Inflammatory Bowel Diseases

Free Subscription 30.06.2025 1 Aliment Pharmacol Ther 2 Am J Gastroenterol 2 Clin Gastroenterol Hepatol 1 Dig Dis 6 Dig Dis Sci 3 Eur J Gastroenterol Hepatol 3 Gastroenterology 2 Gut 7 Inflamm Bowel Dis 3 J Clin Gastroenterol 3 J Crohns Colitis 1 J Immunol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. ROBERTS C, Peters J, Sazonvos A, Goodman N, et al
   Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.
   Aliment Pharmacol Ther. 2025 Jun 23. doi: 10.1111/apt.70232.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. BARNES EL, Raffals L, Qazi T, Deepak P, et al
   A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch.
   Am J Gastroenterol. 2025 Jun 25. doi: 10.14309/ajg.0000000000003608.
   PubMed         Abstract available
   
   
3. MEYER A, Carbonnel F, Dahm CC, Halkjaer J, et al
   Fruits, vegetables, legumes and potatoes and risk of Crohn's disease and ulcerative colitis.
   Am J Gastroenterol. 2025 Jun 24. doi: 10.14309/ajg.0000000000003602.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

4. ATTAUABI M, Madsen GR, Bendtsen F, Seidelin JB, et al
   Multidimensional Patient-Reported Outcomes and Quality of Life at Diagnosis of IBD: A Population-Based Inception Cohort Study.
   Clin Gastroenterol Hepatol. 2025;23:1418-1427.
   PubMed         Abstract available
   
   
5. DURICOVA D, Sonnenberg E, Augustijns P, Mitrova K, et al
   Upadacitinib in Mother with Inflammatory Bowel Disease: Placental Transfer and Breast milk Excretion.
   Clin Gastroenterol Hepatol. 2025 Jun 24:S1542-3565(25)00526.
   PubMed        
   
   

   
   Dig Dis

6. HAYASAKA J, Matsui A, Kikuchi D, Hoteya S, et al
   Impact of therapeutic agents on serum leucine-rich alpha-2 glycoprotein for monitoring endoscopically remitted ulcerative colitis.
   Dig Dis. 2025 Jun 24:1-22. doi: 10.1159/000547007.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

7. IYENGAR M, Jain A, Herfarth HH, Long MD, et al
   MUSings on a Crohn's Disease Diagnosis.
   Dig Dis Sci. 2025 Jun 26. doi: 10.1007/s10620-025-09160.
   PubMed        
   
   
8. STOY S, D'Alessio S, Sandahl TD, Dige A, et al
   Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis.
   Dig Dis Sci. 2025;70:2021-2031.
   PubMed         Abstract available
   
   
9. CLARKE LM, Gupta S, Winter HS, Ryan DP, et al
   Sound of Success: Intestinal Ultrasound in the Management of Refractory Stricturing Crohn's Disease.
   Dig Dis Sci. 2025 Jun 25. doi: 10.1007/s10620-025-09172.
   PubMed         Abstract available
   
   
10. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
    Comment on "Switching to Subcutaneous Infliximab Maintenance Therapy is Effective in Patients with Inflammatory Bowel Disease".
    Dig Dis Sci. 2025 Jun 23. doi: 10.1007/s10620-025-09171.
    PubMed        
    
    
11. MATAR A, Abdelnaem N, Camilleri M
    Bone Broth Benefits: How Its Nutrients Fortify Gut Barrier in Health and Disease.
    Dig Dis Sci. 2025;70:1951-1961.
    PubMed         Abstract available
    
    
12. SODERHOLM JD
    Adding Fat to the Fire: Does Lipidated IL-22 Promote Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Immunomodulators?
    Dig Dis Sci. 2025 Jun 23. doi: 10.1007/s10620-025-09169.
    PubMed        
    
    

    
    Eur J Gastroenterol Hepatol

13. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
    Letter to the editor regarding 'First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn's disease'.
    Eur J Gastroenterol Hepatol. 2025;37:985-986.
    PubMed        
    
    
14. DI PAOLO MC, Cassinotti A, Pagnini C, Ceccarelli L, et al
    Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists.
    Eur J Gastroenterol Hepatol. 2025 Jun 26. doi: 10.1097/MEG.0000000000003025.
    PubMed         Abstract available
    
    
15. RIVA A, Arienti G, Zuin G, Spini L, et al
    Psychological symptoms and alexithymia in adolescents with inflammatory bowel diseases: a case-control study.
    Eur J Gastroenterol Hepatol. 2025;37:917-921.
    PubMed         Abstract available
    
    

    
    Gastroenterology

16. LIU D, Wei Y, Wan J
    Exploring the Role of Wearable Devices in Inflammatory Bowel Disease Management.
    Gastroenterology. 2025 Jun 25:S0016-5085(25)00906.
    PubMed        
    
    
17. WANG P, Wang J, Zhang P, Xiao W, et al
    Comments on "Preclinical protein signatures of Crohn's disease and ulcerative colitis: A nested case-control study within large population-based cohorts".
    Gastroenterology. 2025 Jun 23:S0016-5085(25)00903.
    PubMed        
    
    
18. FRUTKOFF YA, Plotkin L, Pollak D, Livovsky J, et al
    Whole food diet induces remission in children and young adults with mild-moderate Crohn's disease and is more tolerable than exclusive enteral nutrition: a randomized controlled trial.
    Gastroenterology. 2025 Jun 17:S0016-5085(25)00896.
    PubMed         Abstract available
    
    

    
    Gut

19. PAL P, Mateen MA, Pooja K, Marri UK, et al
    Small intestinal contrast ultrasound versus imaging and enteroscopy in Crohn's disease.
    Gut. 2025 Jun 27:gutjnl-2025-335697. doi: 10.1136/gutjnl-2025-335697.
    PubMed        
    
    
20. MORAN GW, Gordon M, Sinopolou V, Radford SJ, et al
    British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025;74.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

21. KOCHHAR GS, Khataniar H, Hashash JG, Regueiro M, et al
    Natural History, Treatment Persistence and Predictors of Treatment Failure in Patients With Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study.
    Inflamm Bowel Dis. 2025 Jun 24:izaf129. doi: 10.1093.
    PubMed         Abstract available
    
    
22. POWERS JC, Westbrook Cates K, Dester E, Zemanek M, et al
    Inflammation of the Rectal Cuff is Associated With Strictures and Fistulas in Patients With Ulcerative Colitis who Have an Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2025 Jun 24:izaf127. doi: 10.1093.
    PubMed         Abstract available
    
    
23. SCHREIBER-STAINTHORP W, Faye AS, Axelrad JE
    Efficacy of Risankizumab Dose Escalation Among Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Jun 24:izaf130. doi: 10.1093.
    PubMed        
    
    
24. HUANG JL, Tan WT, Liu H
    Prostaglandins and Inflammatory Bowel Disease: From Mechanism to Clinic.
    Inflamm Bowel Dis. 2025 Jun 25:izaf121. doi: 10.1093.
    PubMed         Abstract available
    
    
25. FUMERY M, Savoye G, Sarter H, Dupont-Lucas C, et al
    Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease.
    Inflamm Bowel Dis. 2025 Jun 25:izaf133. doi: 10.1093.
    PubMed         Abstract available
    
    
26. FERNANDES SR, Rodrigues IC, Neves ADS, Saraiva S, et al
    Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched Analysis.
    Inflamm Bowel Dis. 2025 Jun 25:izaf112. doi: 10.1093.
    PubMed         Abstract available
    
    
27. MIKHAIL I, Al Ta'ani O, Aburumman R, Alsakarneh S, et al
    Patients With Crohn's Disease and Terminal Ileum Resection are at Increased Risk of Colorectal Cancer: A Population-Based Study.
    Inflamm Bowel Dis. 2025 Jun 18:izaf118. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

28. SCHARL M, Christensen B, Bressler B, Brett NR, et al
    Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease By Disease Location: Results from the EVOLVE Expansion Study.
    J Clin Gastroenterol. 2025 Jun 20. doi: 10.1097/MCG.0000000000002186.
    PubMed         Abstract available
    
    
29. DA CUNHA T, Hagen R, Vaziri H
    Biological Therapies in Inflammatory Bowel Disease: Predictive Factors of Nonresponse.
    J Clin Gastroenterol. 2025 Jun 20. doi: 10.1097/MCG.0000000000002179.
    PubMed         Abstract available
    
    
30. DAI C, Huang YH
    Impact of Clostridioides difficile Infection on the Outcome of Severe Flare of Ulcerative Colitis.
    J Clin Gastroenterol. 2025 Jun 24. doi: 10.1097/MCG.0000000000002217.
    PubMed        
    
    

    
    J Crohns Colitis

31. YZET C, Brazier F, Derval E, Vanelslander P, et al
    Impact of complete vs partial endoscopic healing on long-term outcomes in Crohn's disease: a prospective multicenter study.
    J Crohns Colitis. 2025 Jun 18:jjaf104. doi: 10.1093.
    PubMed         Abstract available
    
    
32. FIORINO G, Fidalgo C, Adamina M, Barreiro-de Acosta M, et al
    Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
    J Crohns Colitis. 2025 Jun 17:jjaf105. doi: 10.1093.
    PubMed         Abstract available
    
    
33. DI VINCENZO F, Quintero MA, Serigado JM, Koru-Sengul T, et al
    Histologic and Endoscopic Findings Are Highly Correlated in a Prospective Cohort of Patients With Inflammatory Bowel Diseases.
    J Crohns Colitis. 2025;19:jjae141.
    PubMed         Abstract available
    
    

    
    J Immunol

34. DASGUPTA D, Tripathi A, Griffard-Smith R, Yellapu N, et al
    Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease.
    J Immunol. 2025 Jun 16:vkaf117. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

35. LIU T, Zhang X, Chen R, Sun Y, et al
    Uncovering common disease mechanisms and critical biomarkers in Crohn's disease with concurrent psoriasis and exploring potential therapeutic agents.
    PLoS One. 2025;20:e0324007.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.